Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00256386
Other study ID # 101-9520 Garfield Mem Trust
Secondary ID
Status Completed
Phase N/A
First received November 17, 2005
Last updated November 29, 2006
Start date January 2004
Est. completion date March 2005

Study information

Verified date November 2005
Source Kaiser Permanente
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Errors and preventable adverse events associated with medication prescription and dispensing are common, and the difference between guideline recommendations and the actual frequency of laboratory monitoring is substantial. This study evaluates three interventions to improve laboratory monitoring at initiation of medication therapy: an electronic medical record reminder to the prescribing clinician (EMR), an automated voice message to the patient (AVM), and a pharmacy team outreach (Pharmacy) compared to usual care (UC).


Description:

Many of the medications that clinicians prescribe to prevent or treat disease can result in unanticipated and unintended toxic effects. Many national clinical guidelines recommend baseline and periodic laboratory monitoring to avoid adverse drug events. Our Safety in Prescribing project (SIP) has found many significant gaps in medication safety. Lab Alert will evaluate electronic tools to improve Kaiser Permanente's performance in laboratory monitoring to avoid adverse drug events. We will enroll patients who are taking high-risk medications and who have not received laboratory monitoring. The primary outcome of this 2-year study is the proportion of patients who receive guideline-based laboratory monitoring at 1 and 3 weeks post-intervention.

Fifteen primary care clinics will be randomly assigned to: (1) usual care (UC) (2) electronic message reminder (EMR) (3) automated voice message (AVM) (4) pharmacy outreach team (Pharmacy). The reminders will notify of the patient's need for guideline-specified laboratory testing due to medication use. Using electronic data, patients with PCPs assigned to intervention clinics who are on study-specified medications will be identified and screened for exclusions, to yield 600 patients (200 per intervention group). Patients will be assigned to the treatment groups on the basis of the condition assigned to their usual clinic. After the intervention and observation periods, and using the same time frame and inclusion and exclusion criteria used to identify the patients in the intervention arms, we will retrospectively identify a comparison 200-patient cohort in the usual care clinics. Thus, approximately 800 patients will be included in the study. Baseline, follow-up, and outcome data will be obtained from electronic records.

Study-defined medications will be finalized by the study team and quality committees. These medications are identified based upon previous work and are prescribed with reasonable frequency, commonly have gaps in laboratory monitoring, carry significant risk of toxicity, and are of interest to the participating HMOs because of prior and potential adverse events. We anticipate focusing on baseline monitoring for new prescriptions. New starts will be defined as patients with an index prescription but no other dispense of that medication in the prior 6 months.

Lab Alert will assess the effectiveness of a patient-specific electronic medical record (EMR) in-basket reminder to the primary care provider (PCP) (EMR reminder), an automated recorded voice message to the patient (AVM), pharmacy team outreach (Pharmacy) to increase the proportion of patients receiving all guideline-based laboratory monitoring, when compared to usual care (UC). If any intervention is better than UC, Lab Alert will assess and compare their effectiveness and costs. The study also will evaluate PCP and patient experiences with the intervention in order to refine the interventions in the future.


Recruitment information / eligibility

Status Completed
Enrollment 800
Est. completion date March 2005
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Dispensed one of 12 drugs or classes of drugs where baseline safety laboratory monitoring is recommended and labs have not been completed 6 months prior or 5 days after the dispense of the medication.

- 18 years of age or older

- 12-month HMO membership

- drug benefit coverage

- has telephone number

Exclusion Criteria:

- recommended baseline laboratory monitoring completed

- receives care and/or resides in hospice, nursing home, care outside HMO

- enrolled in other care management program

- nonEnglish speaking needing translation services

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Device:
Electronic Medical Record (EMR) to clinician's in-basket

Automated Voice Message (AVM) reminder to patient's phone

Procedure:
Pharmacy Team phone call-letter followup


Locations

Country Name City State
United States Kaiser Permanente Center for Health Research Portland Oregon

Sponsors (2)

Lead Sponsor Collaborator
Kaiser Permanente Garfield Memorial Fund

Country where clinical trial is conducted

United States, 

References & Publications (44)

Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med. 2001 Jan 8;161(1):53-8. — View Citation

Balas EA, Boren SA, Griffing G. Computerized management of diabetes: a synthesis of controlled trials. Proc AMIA Symp. 1998:295-9. — View Citation

Balas EA, Weingarten S, Garb CT, Blumenthal D, Boren SA, Brown GD. Improving preventive care by prompting physicians. Arch Intern Med. 2000 Feb 14;160(3):301-8. — View Citation

Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995 Jul 5;274(1):29-34. — View Citation

Bates DW. Using information technology to reduce rates of medication errors in hospitals. BMJ. 2000 Mar 18;320(7237):788-91. — View Citation

Beach JE, Faich GA, Bormel FG, Sasinowski FJ. Black box warnings in prescription drug labeling: results of a survey of 206 drugs. Food Drug Law J. 1998;53(3):403-11. — View Citation

Beard K. Adverse reactions as a cause of hospital admission in the aged. Drugs Aging. 1992 Jul-Aug;2(4):356-67. Review. — View Citation

Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, Newhouse JP, Weiler PC, Hiatt HH. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med. 1991 Feb 7;324(6):370-6. — View Citation

Burnum JF. Letter: Preventability of adverse drug reactions. Ann Intern Med. 1976 Jul;85(1):80-1. — View Citation

Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care. 1995 Aug;33(8):783-95. — View Citation

Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997 Jan 22-29;277(4):301-6. — View Citation

Delichatsios HK, Friedman RH, Glanz K, Tennstedt S, Smigelski C, Pinto BM, Kelley H, Gillman MW. Randomized trial of a "talking computer" to improve adults' eating habits. Am J Health Promot. 2001 Mar-Apr;15(4):215-24. — View Citation

Discount usability testing of computer-generated clinical alerts uncovers flaws. Denver, CO: 2003.

Feldstein A, Elmer PJ, Smith DH, Herson M, Orwoll E, Chen C, Aickin M, Swain MC. Electronic medical record reminder improves osteoporosis management after a fracture: a randomized, controlled trial. J Am Geriatr Soc. 2006 Mar;54(3):450-7. — View Citation

Feldstein AC, Smith DH, Perrin N, Yang X, Rix M, Raebel MA, Magid DJ, Simon SR, Soumerai SB. Improved therapeutic monitoring with several interventions: a randomized trial. Arch Intern Med. 2006 Sep 25;166(17):1848-54. — View Citation

Feldstein AC, Smith DH, Robertson NR, Kovach CA, Soumerai SB, Simon SR, Sittig DF, Laferriere DS, Kalter M. Decision Support System Design and Implementation for Outpatient Prescribing: The Safety in Prescribing Study. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in Patient Safety: From Research to Implementation (Volume 3: Implementation Issues). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Feb. — View Citation

Freeborn DK PC. Promise and performance in managed care. Greenlick M, Freeborn D, Pope C, editors. 1994. Baltimore, MD, Johns Hopkins University Press.

Friedman RH, Kazis LE, Jette A, Smith MB, Stollerman J, Torgerson J, Carey K. A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. Am J Hypertens. 1996 Apr;9(4 Pt 1):285-92. — View Citation

Friedman RH, Stollerman J, Rozenblyum L, Belfer D, Selim A, Mahoney D, Steinbach S. A telecommunications system to manage patients with chronic disease. Stud Health Technol Inform. 1998;52 Pt 2:1330-4. — View Citation

Gandhi TK, Burstin HR, Cook EF, Puopolo AL, Haas JS, Brennan TA, Bates DW. Drug complications in outpatients. J Gen Intern Med. 2000 Mar;15(3):149-54. — View Citation

Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. JAMA. 2001 Aug 15;286(7):831-3. — View Citation

Hoch I, Heymann AD, Kurman I, Valinsky LJ, Chodick G, Shalev V. Countrywide computer alerts to community physicians improve potassium testing in patients receiving diuretics. J Am Med Inform Assoc. 2003 Nov-Dec;10(6):541-6. Epub 2003 Aug 4. — View Citation

Hosmer DWJr, Lemeshow S. Applied survival analysis: Regression modeling of time to event data. New York: Wiley and Sons, 1999.

Hulse RK, Clark SJ, Jackson JC, Warner HR, Gardner RM. Computerized medication monitoring system. Am J Hosp Pharm. 1976 Oct;33(10):1061-4. — View Citation

Kaushal R, Shojania KG, Bates DW. Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med. 2003 Jun 23;163(12):1409-16. Review. — View Citation

Krishna S, Balas EA, Boren SA, Maglaveras N. Patient acceptance of educational voice messages: a review of controlled clinical studies. Methods Inf Med. 2002;41(5):360-9. Review. — View Citation

Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, Hebert L, Newhouse JP, Weiler PC, Hiatt H. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991 Feb 7;324(6):377-84. — View Citation

Leirer VO, Morrow DG, Pariante G, Doksum T. Increasing influenza vaccination adherence through voice mail. J Am Geriatr Soc. 1989 Dec;37(12):1147-50. — View Citation

Lesar TS, Briceland L, Stein DS. Factors related to errors in medication prescribing. JAMA. 1997 Jan 22-29;277(4):312-7. — View Citation

Linkins RW, Dini EF, Watson G, Patriarca PA. A randomized trial of the effectiveness of computer-generated telephone messages in increasing immunization visits among preschool children. Arch Pediatr Adolesc Med. 1994 Sep;148(9):908-14. — View Citation

Piette JD, Mah CA. The feasibility of automated voice messaging as an adjunct to diabetes outpatient care. Diabetes Care. 1997 Jan;20(1):15-21. — View Citation

Poon EG, Gandhi TK, Sequist TD, Murff HJ, Karson AS, Bates DW. "I wish I had seen this test result earlier!": Dissatisfaction with test result management systems in primary care. Arch Intern Med. 2004 Nov 8;164(20):2223-8. — View Citation

Raebel MA, Lyons EE, Andrade SE, Chan KA, Chester EA, Davis RL, Ellis JL, Feldstein A, Gunter MJ, Lafata JE, Long CL, Magid DJ, Selby JV, Simon SR, Platt R. Laboratory monitoring of drugs at initiation of therapy in ambulatory care. J Gen Intern Med. 2005 Dec;20(12):1120-6. — View Citation

Raebel MA, Lyons EE, Chester EA, Bodily MA, Kelleher JA, Long CL, Miller C, Magid DJ. Improving laboratory monitoring at initiation of drug therapy in ambulatory care: a randomized trial. Arch Intern Med. 2005 Nov 14;165(20):2395-401. — View Citation

Raudenbush S, Bryk A, Cheong YF, Congdon R. HLM 5 hierarchical linear and nonlinear modeling. Lincolnwood: Scientific Software International, 2001.

Rind DM, Safran C, Phillips RS, Wang Q, Calkins DR, Delbanco TL, Bleich HL, Slack WV. Effect of computer-based alerts on the treatment and outcomes of hospitalized patients. Arch Intern Med. 1994 Jul 11;154(13):1511-7. — View Citation

Schiff GD, Klass D, Peterson J, Shah G, Bates DW. Linking laboratory and pharmacy: opportunities for reducing errors and improving care. Arch Intern Med. 2003 Apr 28;163(8):893-900. Review. — View Citation

Selby JV, Ettinger B, Swain BE, Brown JB. First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care. 1999 Jan;22(1):38-44. — View Citation

Shea S, DuMouchel W, Bahamonde L. A meta-analysis of 16 randomized controlled trials to evaluate computer-based clinical reminder systems for preventive care in the ambulatory setting. J Am Med Inform Assoc. 1996 Nov-Dec;3(6):399-409. — View Citation

Simon SR, Andrade SE, Ellis JL, Nelson WW, Gurwitz JH, Lafata JE, Davis RL, Feldstein A, Raebel MA. Baseline laboratory monitoring of cardiovascular medications in elderly health maintenance organization enrollees. J Am Geriatr Soc. 2005 Dec;53(12):2165-9. — View Citation

Skipwith DH. Telephone counseling interventions with caregivers of elders. J Psychosoc Nurs Ment Health Serv. 1994 Mar;32(3):7-12. — View Citation

Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med. 2003 Mar 24;163(6):688-92. — View Citation

Tanke ED, Leirer VO. Automated telephone reminders in tuberculosis care. Med Care. 1994 Apr;32(4):380-9. — View Citation

Thomas EJ, Studdert DM, Burstin HR, Orav EJ, Zeena T, Williams EJ, Howard KM, Weiler PC, Brennan TA. Incidence and types of adverse events and negligent care in Utah and Colorado. Med Care. 2000 Mar;38(3):261-71. — View Citation

* Note: There are 44 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary The number of patients that complete recommended laboratory monitoring within one week and twenty five days after intervention.
Primary The study will evaluate the time to completion of the recommended labs.
Primary The study will also evaluate PCP and patient experiences with the interventions in order to refine the interventions in the future.
See also
  Status Clinical Trial Phase
Recruiting NCT05073744 - Nalbuphine Versus Morphine for Perioperative Tumor Ablation Phase 4
Completed NCT03969641 - Safety of RIV4 Versus IIV4 in Pregnant Women Phase 4
Completed NCT05592951 - Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers N/A
Completed NCT04693429 - Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ Phase 1
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01243502 - A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers Phase 1
Completed NCT06072170 - Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience Phase 1
Completed NCT05076253 - Efficacy of Ivermectin in COVID-19 Phase 1/Phase 2
Recruiting NCT06060379 - Giochiamo 626 - Gaming for Health and Safety in Workplaces N/A
Recruiting NCT05298800 - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Phase 4
Completed NCT05188638 - Safety of Ascending Single and Multiple Doses of Nebulised SoftOx Inhalation Solution in Healthy Subjects Phase 1
Completed NCT05145621 - Oral Bio-equivalence Study Phase 1
Recruiting NCT05580159 - New Generation mRNA Booster Vaccine Against Emerging VOCs Phase 3
Not yet recruiting NCT04596956 - Safety and Efficacy of Sodium Bicarbonate Ringer Injection Phase 4
Completed NCT03033329 - Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4 Phase 1
Terminated NCT01929811 - NeoMET Study in Neoadjuvant Treatment of Breast Cancer Phase 2
Completed NCT01193335 - Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants. Phase 4
Completed NCT03300466 - A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds N/A
Active, not recruiting NCT05686161 - mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs Phase 3